18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

PHASE4CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions
Type 2 DiabetesHypertension
Interventions
DRUG

Amlodipine

Amlodipine 5 mg tablets , Daily for 3 weeks;

DRUG

amlodipine / olmesartan medoxomil combination

amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg

DRUG

Hydrochlorothiazide

hydrochlorothiazide tablets, 12.5 mg or 25 mg.

Trial Locations (21)

Unknown

Los Angeles

Sylmar

Tustin

Aventura

DeLand

Hialeah

Pembroke Pines

Avon

Indianapolis

Las Vegas

New Windsor

Winston-Salem

Cincinnati

Oklahoma City

Charleston

Greer

Taylors

Nashville

Dallas

San Antonio

Burke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY